AstraZeneca PLC (LSE:AZN) — Market Cap & Net Worth
Market Cap & Net Worth: AstraZeneca PLC (AZN)
AstraZeneca PLC (LSE:AZN) has a market capitalization of $2.27 Billion (GBX18.67 Trillion) as of August 6, 2026. Listed on the LSE stock exchange, this UK-based company holds position #5743 globally and #12 in its home market, demonstrating a -6.61% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying AstraZeneca PLC's stock price GBX12036.00 by its total outstanding shares 1550876987 (1.55 Billion). See reinvestment intensity of AstraZeneca PLC to understand how much of operating cash flow is reinvested back into capital assets.
AstraZeneca PLC Market Cap History: 2015 to 2026
AstraZeneca PLC's market capitalization history from 2015 to 2026. Data shows growth from $653.79 Million to $2.27 Billion (13.31% CAGR).
Index Memberships
AstraZeneca PLC is a constituent of 6 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE All-Share
FTAS
|
$72.47 Billion | 3.13% | #4 of 573 |
|
FTSE 350
FTLC
|
$72.05 Billion | 3.15% | #4 of 350 |
|
FTSE 100 Index (UK)
FTSE
|
$56.25 Billion | 4.04% | #3 of 100 |
|
STOXX Europe Large 200 EUR Price
LCXP
|
$7.23 Trillion | 0.03% | #114 of 182 |
|
STOXX Europe Large 200 Net Return
LCXR
|
$7.23 Trillion | 0.03% | #114 of 182 |
|
FTSE 350 Pharmaceuticals & Biotechnology
NMX4570
|
$3.29 Billion | 69.10% | #1 of 6 |
Weight: AstraZeneca PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
AstraZeneca PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how AstraZeneca PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.04x
AstraZeneca PLC's market cap is 0.04 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.25x
AstraZeneca PLC's market cap is 0.25 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $657.03 Million | $20.92 Billion | $3.18 Billion | 0.03x | 0.21x |
| 2017 | $795.52 Million | $23.45 Billion | $3.13 Billion | 0.03x | 0.25x |
| 2018 | $949.13 Million | $20.99 Billion | $2.05 Billion | 0.05x | 0.46x |
| 2019 | $1.27 Billion | $24.50 Billion | $1.34 Billion | 0.05x | 0.95x |
| 2020 | $1.26 Billion | $29.27 Billion | $3.39 Billion | 0.04x | 0.37x |
| 2021 | $1.53 Billion | $37.11 Billion | $109.85 Million | 0.04x | 13.96x |
| 2022 | $2.03 Billion | $44.25 Billion | $3.28 Billion | 0.05x | 0.62x |
| 2023 | $1.96 Billion | $46.58 Billion | $6.06 Billion | 0.04x | 0.32x |
| 2024 | $1.98 Billion | $52.94 Billion | $6.89 Billion | 0.04x | 0.29x |
| 2025 | $2.60 Billion | $58.74 Billion | $10.22 Billion | 0.04x | 0.25x |
Competitor Companies of AZN by Market Capitalization
Companies near AstraZeneca PLC in the global market cap rankings as of August 6, 2026.
Key companies related to AstraZeneca PLC by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #14 globally with a market cap of $936.50 Billion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #17 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Johnson & Johnson (NYSE:JNJ): Ranked #27 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #42 globally with a market cap of $356.49 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #14 | Eli Lilly and Company | NYSE:LLY | $936.50 Billion | $1169.86 |
| #17 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #27 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $257.59 |
| #42 | AbbVie Inc | NYSE:ABBV | $356.49 Billion | $246.20 |
AstraZeneca PLC Historical Marketcap From 2015 to 2026
Between 2015 and today, AstraZeneca PLC's market cap moved from $653.79 Million to $ 2.27 Billion, with a yearly change of 13.31%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX2.27 Billion | -12.72% |
| 2025 | GBX2.60 Billion | +31.73% |
| 2024 | GBX1.98 Billion | +0.92% |
| 2023 | GBX1.96 Billion | -3.53% |
| 2022 | GBX2.03 Billion | +32.32% |
| 2021 | GBX1.53 Billion | +21.78% |
| 2020 | GBX1.26 Billion | -0.99% |
| 2019 | GBX1.27 Billion | +33.98% |
| 2018 | GBX949.13 Million | +19.31% |
| 2017 | GBX795.52 Million | +21.08% |
| 2016 | GBX657.03 Million | +0.50% |
| 2015 | GBX653.79 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 6th, 2026 the market cap of AstraZeneca PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.27 Billion USD |
| MoneyControl | $2.27 Billion USD |
| MarketWatch | $2.27 Billion USD |
| marketcap.company | $2.27 Billion USD |
| Reuters | $2.27 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splend… Read more